Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society
(This g...uideline was simultaneously published in The Pediatric Infectious Disease Journal on November 6, 2013.)
more
Guideline
SAJHIVMED DECEMBER 2013, Vol. 14, No. 4
Pan African Medical Journal 2017;27:215. doi: 10.11604/pamj.2017.27.215.12994
In the context of the Support to National Malaria Control Programme (SuNMaP), demand creation is the strategic combination of advocacy, communication and mobilisation approaches that seek to achieve increased community awareness of, and demand for, effective malaria prevention and treatment services.... For malaria treatment, demand creation focuses on promoting improved testing, prompt and proper use of artemisinin combination therapy (ACT) treatment for individual cases of malaria, and effective home management of fever, together with referrals of severe cases to a higher-level health facility.
more
J Pediatr Rev 2015, vol.3 (1) e361
The purpose of the handbook is to provide those involved in nutrition coordination with relevant tools, guidance, information and resources to support their roles in facilitating predictable, coordinated and effective preparation for, and responses to, nutrition needs in humanitarian emergencies. Ra...ther than being prescriptive, the handbook aims to raises key issues encountered to date.
more
Oсобенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (Covid-19) у детей (clinical guidelines pediatrics)
Many low- and middle-income countries (LMICs) are undergoing an epidemiological transition. With an improvement in socioeconomic conditions and an aging population, cardiovascular diseases (CVDs), like cardiac arrhythmias, are expected to increase in these countries. However, there are limited studi...es on the epidemiology and management of cardiac arrhythmias in LMICs. This review will highlight the unique challenges and opportunities that these countries face when managing cardiac arrhythmias.
more
BMJ 2020;368:m1052 doi: 10.1136/bmj.m1052 (Published 13 March 2020)
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
PlosOne https://doi.org/10.1371/journal.pone.0161576; Zoonotic diseases have varying public health burden and socio-economic impact across time and geographical settings making their prioritization for prevention and control important at the national level. We conducted systematic prioritization of ...zoonotic diseases and developed a ranked list of these diseases that would guide allocation of resources to enhance their surveillance, prevention, and control.
more
Research
BMJ 2014;349:g4643 doi: 10.1136/bmj.g4643 (Published 5 August 2014), 1-11
Climate change is increasing the risks of injuries, diseases, and deaths globally. However, the association between ambient temperature and renal diseases has not been fully characterized. This study aimed to quantify the risk and attributable burden for hospitalizations of renal diseases related to... ambient temperature.
more
Clinical Medicine
JCI Insight. 2017;2(7):e91963.
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more